Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Epilepsy × enzalutamide × Genitourinary × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 172 Prostatic Neoplasms, Castration-Resistant 19 Neoplasm Metastasis 18 Metastatic Castration Resistant Prostate Cancer 9 Prostate Cancer Metastatic 7 Metastatic Castration-Resistant Prostate Cancer 7 Metastatic Castration-resistant Prostate Cancer 4 Melanoma 4 Castration-resistant Prostate Cancer 4 Breast Neoplasms 4 Prostate Adenocarcinoma 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Pancreatic Neoplasms 3 Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Bulbo-Spinal Atrophy, X-Linked 3 Adenocarcinoma 3 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Non-metastatic Castration-resistant Prostate Cancer 2 Metastatic Hormone-sensitive Prostate Cancer 2 Metastatic Hormone Sensitive Prostate Cancer 2 Metastatic Castration-resistant Prostate Cancer (mCRPC) 2 Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2 Lymphoma, Non-Hodgkin 2 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Castration Resistant Metastatic Prostate Cancer 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04290611 2023-04-13

VENDY

Groupe Hospitalier Pitie-Salpetriere

500,000 enrolled

Brain Diseases, Epilepsy, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡